#United States #Columbus #Clinical Trials #Paradigm Health #EHR-integrated

Introduction

In a significant advancement for clinical research, recent peer-reviewed studies have highlighted the successful application of Paradigm Health's EHR-integrated eSource platform. This innovation aims to transform late-stage clinical research, particularly within community oncology settings. The study, extensively supported by Johnson & Johnson, explores the feasibility of an integrated electronic health record (EHR) system in streamlining data collection processes.

Study Overview

The research team conducted a prospective observational study across four community oncology sites, most notably the New York Cancer and Blood Specialists in Babylon, New York, and Clearview Cancer Institute in Huntsville, Alabama. This study focused on gathering real-world data concerning infusion-related adverse events (AEs) in patients diagnosed with multiple myeloma and treated with daratumumab.

The primary goal was to evaluate whether the EHR-integrated platform could not only facilitate data collection but also support the efficient management of patient identification and enrollment processes.

Key Findings and Statistics

The outcomes of the pilot study were noteworthy:

• - Patient Enrollment: 82 patients were successfully enrolled in less than one year, surpassing enrollment targets three months ahead of schedule.
• - Data Collection: Researchers amassed over 4,500 data elements across the involved sites, with more than 90% eligible for automated transfer from EHRs to the study database.
• - Data Transfer Speed: The rapid data transfer rate through the EHR-to-data capture connector averaged just 1.7 days, a significant improvement compared to traditional methods.
• - Query Frequency: The study exhibited a sponsor query frequency of less than 2%, which is substantially lower than the typical 5.2% for manually entered data.

Implications for Community Oncology

The implications of these findings are promising for community oncology centers across the United States. The study demonstrates that EHR-integrated tools can facilitate rapid enrollment and improve data completeness, positioning community providers as pivotal players in clinical research. According to Dr. Richard Zuniga, a key author of the study and a medical oncologist, "These pragmatically designed and technology-enabled trials can fundamentally change the landscape of cancer research."

Paradigm Health's Commitment

Kent Thoelke, founder and CEO of Paradigm Health, emphasized that this research substantiates the potential of their technology to enhance accessibility to clinical research for community healthcare providers. The eSource Casebook expands capabilities by minimizing data transcription burdens, thereby hastening data transmission to trial sponsors. This shift allows more healthcare professionals to engage in clinical research, benefiting a broader patient population.

Traditional models often involve convoluted data entries across independent systems, which can deter providers from participating in clinical trials due to the additional workload. Paradigm Health resolves these issues by embedding research into the existing clinical workflows, ensuring data integrity while streamlining processes.

Conclusion

Paradigm Health's integration of Clinical Pipe with its eSource Casebook technology signifies a meaningful evolution in clinical research frameworks. By leveraging EHR-integrated platforms, they are not only enhancing study processes but also paving the way for equitable access to groundbreaking therapies. This technological advancement represents hope for many patients and reflects a commitment to improving cancer research methodologies across diverse healthcare settings.

For more information on Paradigm Health and their innovative solutions, visit Paradigm Health.